Stifel is a full-service investment bank with deep industry experience. We serve as strategic advisors to entrepreneurs, family-owned businesses, private equity groups, and leading public and private corporations in North America, Europe, Asia, and Latin America. Our full-service healthcare investment banking practice offers a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise. We are not bound by borders. We stand ready to provide the insight and expertise you require. Our integrated approach allows us to deliver the full capabilities of Stifel’s institutional capital markets platform and retail brokerage network, which are among the most highly regarded in the industry.

InvestHK’s vision is to strengthen Hong Kong’s status as the leading international finance and business hub. Our mission is facilitate and promote economically and strategically important investment, both inward and outward, to support the economic development of Hong Kong.

BIOSAXONY, the visionary cluster for biotech, medtech and health industry in Central Germany, is forming a unique alliance of national and international life science stakeholders and a strong clinical ecosystem within the heart of Europe. We initiate innovative projects between industry and science and operate the innovation center BIO CITY Leipzig. With MEDICAL FORGE we provide an accelerator for international medtech teams, with 12 months intensive coaching, state of-the-art coworking laboratories and exclusive access to our extensive clinical and industrial network. Application is open until: 30.11.2024 on the website.

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Principal Investments, Planetary Health Investments and Asia teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.